Viral clearance Market Expected to Reach $977.8 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Viral clearance Market," The viral clearance market size was $425.93 million in 2021, and is estimated to reach $977.8 million by 2031, growing at a CAGR of 8.6% from 2022 to 2031.

Viral detection and clearance is performed to demonstrate clearance of viruses known to be related to a process. Viral clearance services industry are useful before launching a biologic to the market.

There is no such test present to detect all viruses at once, which lead to a minimum level of viruses test for detection. Some methods measure markers of infection, providing results long after infection occurs. Hence, ensuring that a product is free from viral contamination depends on ensuring that a process can inactivate or remove viruses as well as testing for their presence. Such an approach is the only way to ensure that biopharmaceuticals will be free from viral contamination and safe for human use. It is also important to recognize which viruses can possibly contaminate a product and enter its manufacturing process.

The viral clearance market is segmented on the basis of method, application, end user, and region. By method, it is categorized into viral removal, and viral inactivation. Viral removal is further divided into chromatography, nanofiltration, and precipitation. Viral inactivation is further categorized into low pH, solvent detergent method, heat pasteurization, and other viral inactivation methods. Depending on application, it is classified into recombinant proteins, blood and blood products, cellular and gene therapy products, vaccines, and other applications. By end user, it is categorized into pharmaceutical & biotechnology companies, contract research organizations, academic research institutes, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

By method, the viral removal segment currently dominates the global viral clearance market share and is expected to remain dominant during the forecast period, owing to increase in awareness about the benefits of using viral removals among healthcare professionals and consumers fueling the demand for the viral removals. By application, the recombinant proteins segment dominated the market in 2021, and this trend is expected to continue during the forecast period owing to continuous rise of chronic illnesses across the globe. Apart from the surge in chronic diseases, the rise in funding of the worldwide government on R&D activities are also fuelling the viral clearance market growth efficiently. By end user, the pharmaceutical and biotechnology companies segment dominated the market in 2021, and this trend is expected to continue during the forecast period owing to increase in utilization of viral clearance processing during production of biopharmaceuticals, and key players operating in the market are adopting various key strategies to expand their business and rising investment on R&D segment, these also form key viral clearance market trends.

By region, North America accounted for the largest market share in the viral clearance testing industry in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in demand for biopharmaceutical and upsurge in demand for advanced technologies in the purification of recombinant proteins produced by animal cell cultures to create high-value products of modern biotechnology.

Asia-Pacific witnessed the highest growth rate for the viral clearance market and is expected to continue this trend throughout the forecast period, which is attributed to its R&D activities for biopharmaceuticals, rise in investments made by the market players and increase in government support.

The report provides a comprehensive analysis of the key players that operate in the global viral clearance market. The key companies profiled in the report include Allure Medical Group, Charles River Laboratories International, Inc., Clean Cells, Creative Biogene, Eurofins Scientific SE, Maravai Lifesciences Holding, Inc., Merck KGaA, Sartorius Stedium Biotech, Syngene International Limited, and Wuxi Biologics Inc.

KEY FINDINGS OF THE STUDY

• On the basis of method, the viral removal segment held 59.39% share in the global market in 2021.
• On the basis of application, the recombinant proteins segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
• On the basis of end user, the pharmaceutical and biotechnology companies segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
• Region wise, North America is expected to experience the highest market share during the forecast period. This was attributed to biopharmaceutical and upsurge in demand for advanced technologies in the purification of recombinant proteins produced by animal cell cultures to create high-value products of modern biotechnology.